Seres Reports Preclinical SER-428 Data and Plans Phase 1b Trial

Seres Therapeutics reported up to 1,000-fold reduction in GI pathogens in preclinical data for its liquid live biotherapeutic SER-428. It plans an open-label Phase 1b MICU trial, pending funding.